NovoCure Limited (NVCR) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Instruments & Supplies Branche. Der Hauptsitz des Unternehmens ist in Saint Helier, Jersey. Der aktuelle CEO ist Frank Leonard.
NVCR hat IPO-Datum 2015-10-01, 1,488 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $1.38B.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
